Molecular factors associated with pemetrexed sensitivity according to histological type in non-small cell lung cancer

Tsukihisa Yoshida, Tatsuro Okamoto, Tokujiro Yano, Kazuki Takada, Mikihiro Kohno, Kenichi Suda, Mitsuhiro Takenoyama, Yoshinao Oda, Yoshihiko Maehara

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: This study was designed to investigate potential molecules that predict chemosensitivity to pemetrexed (Alimta®) in surgically resected non-small cell lung cancer (NSCLC). Materials and Methods: Chemosensitivity to ALM and other drugs was assessed by succinate dehydrogenase inhibition (SDI) test in 69 NSCLC samples (55 adenocarcinomas, and 14 squamous cell carcinomas). The mRNA expression levels of Alimta®-target enzymes [thymidylate synthase (TYMS); dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT)], Alimta®-metabolizing enzymes [γ-glutamyl hydrase (GGH) and folylpolyglutamate synthase] and an Alimta® transporter [reduce folate carrier (RFC)] were measured and examined for potential correlations to chemosensitivity. Results: The squamous cell carcinoma samples showed higher TYMS expression and lower RFC expression than did the adenocarcinoma samples. In the adenocarcinoma sample analyses, GGH expression was inversely correlated to sensitivity. Conclusion: The histology-dependent differences in chemosensitivity to Alimta® may be attributed to the histology-dependent differences in TYMS and RFC expression. In adenocarcinomas, GGH potentially represents a marker for chemosensitivity to Alimta®.

Original languageEnglish
Pages (from-to)6319-6326
Number of pages8
JournalAnticancer research
Volume36
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Pemetrexed
Non-Small Cell Lung Carcinoma
Thymidylate Synthase
Adenocarcinoma
Folic Acid
Folic Acid Transporters
Squamous Cell Carcinoma
Histology
Hydroxymethyl and Formyl Transferases
Hydro-Lyases
Tetrahydrofolate Dehydrogenase
Succinate Dehydrogenase
Enzymes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Molecular factors associated with pemetrexed sensitivity according to histological type in non-small cell lung cancer. / Yoshida, Tsukihisa; Okamoto, Tatsuro; Yano, Tokujiro; Takada, Kazuki; Kohno, Mikihiro; Suda, Kenichi; Takenoyama, Mitsuhiro; Oda, Yoshinao; Maehara, Yoshihiko.

In: Anticancer research, Vol. 36, No. 12, 01.12.2016, p. 6319-6326.

Research output: Contribution to journalArticle

Yoshida, T, Okamoto, T, Yano, T, Takada, K, Kohno, M, Suda, K, Takenoyama, M, Oda, Y & Maehara, Y 2016, 'Molecular factors associated with pemetrexed sensitivity according to histological type in non-small cell lung cancer', Anticancer research, vol. 36, no. 12, pp. 6319-6326. https://doi.org/10.21873/anticanres.11228
Yoshida, Tsukihisa ; Okamoto, Tatsuro ; Yano, Tokujiro ; Takada, Kazuki ; Kohno, Mikihiro ; Suda, Kenichi ; Takenoyama, Mitsuhiro ; Oda, Yoshinao ; Maehara, Yoshihiko. / Molecular factors associated with pemetrexed sensitivity according to histological type in non-small cell lung cancer. In: Anticancer research. 2016 ; Vol. 36, No. 12. pp. 6319-6326.
@article{1dbe3d3d24074ee8b1319244c23c7318,
title = "Molecular factors associated with pemetrexed sensitivity according to histological type in non-small cell lung cancer",
abstract = "Background: This study was designed to investigate potential molecules that predict chemosensitivity to pemetrexed (Alimta{\circledR}) in surgically resected non-small cell lung cancer (NSCLC). Materials and Methods: Chemosensitivity to ALM and other drugs was assessed by succinate dehydrogenase inhibition (SDI) test in 69 NSCLC samples (55 adenocarcinomas, and 14 squamous cell carcinomas). The mRNA expression levels of Alimta{\circledR}-target enzymes [thymidylate synthase (TYMS); dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT)], Alimta{\circledR}-metabolizing enzymes [γ-glutamyl hydrase (GGH) and folylpolyglutamate synthase] and an Alimta{\circledR} transporter [reduce folate carrier (RFC)] were measured and examined for potential correlations to chemosensitivity. Results: The squamous cell carcinoma samples showed higher TYMS expression and lower RFC expression than did the adenocarcinoma samples. In the adenocarcinoma sample analyses, GGH expression was inversely correlated to sensitivity. Conclusion: The histology-dependent differences in chemosensitivity to Alimta{\circledR} may be attributed to the histology-dependent differences in TYMS and RFC expression. In adenocarcinomas, GGH potentially represents a marker for chemosensitivity to Alimta{\circledR}.",
author = "Tsukihisa Yoshida and Tatsuro Okamoto and Tokujiro Yano and Kazuki Takada and Mikihiro Kohno and Kenichi Suda and Mitsuhiro Takenoyama and Yoshinao Oda and Yoshihiko Maehara",
year = "2016",
month = "12",
day = "1",
doi = "10.21873/anticanres.11228",
language = "English",
volume = "36",
pages = "6319--6326",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

TY - JOUR

T1 - Molecular factors associated with pemetrexed sensitivity according to histological type in non-small cell lung cancer

AU - Yoshida, Tsukihisa

AU - Okamoto, Tatsuro

AU - Yano, Tokujiro

AU - Takada, Kazuki

AU - Kohno, Mikihiro

AU - Suda, Kenichi

AU - Takenoyama, Mitsuhiro

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: This study was designed to investigate potential molecules that predict chemosensitivity to pemetrexed (Alimta®) in surgically resected non-small cell lung cancer (NSCLC). Materials and Methods: Chemosensitivity to ALM and other drugs was assessed by succinate dehydrogenase inhibition (SDI) test in 69 NSCLC samples (55 adenocarcinomas, and 14 squamous cell carcinomas). The mRNA expression levels of Alimta®-target enzymes [thymidylate synthase (TYMS); dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT)], Alimta®-metabolizing enzymes [γ-glutamyl hydrase (GGH) and folylpolyglutamate synthase] and an Alimta® transporter [reduce folate carrier (RFC)] were measured and examined for potential correlations to chemosensitivity. Results: The squamous cell carcinoma samples showed higher TYMS expression and lower RFC expression than did the adenocarcinoma samples. In the adenocarcinoma sample analyses, GGH expression was inversely correlated to sensitivity. Conclusion: The histology-dependent differences in chemosensitivity to Alimta® may be attributed to the histology-dependent differences in TYMS and RFC expression. In adenocarcinomas, GGH potentially represents a marker for chemosensitivity to Alimta®.

AB - Background: This study was designed to investigate potential molecules that predict chemosensitivity to pemetrexed (Alimta®) in surgically resected non-small cell lung cancer (NSCLC). Materials and Methods: Chemosensitivity to ALM and other drugs was assessed by succinate dehydrogenase inhibition (SDI) test in 69 NSCLC samples (55 adenocarcinomas, and 14 squamous cell carcinomas). The mRNA expression levels of Alimta®-target enzymes [thymidylate synthase (TYMS); dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT)], Alimta®-metabolizing enzymes [γ-glutamyl hydrase (GGH) and folylpolyglutamate synthase] and an Alimta® transporter [reduce folate carrier (RFC)] were measured and examined for potential correlations to chemosensitivity. Results: The squamous cell carcinoma samples showed higher TYMS expression and lower RFC expression than did the adenocarcinoma samples. In the adenocarcinoma sample analyses, GGH expression was inversely correlated to sensitivity. Conclusion: The histology-dependent differences in chemosensitivity to Alimta® may be attributed to the histology-dependent differences in TYMS and RFC expression. In adenocarcinomas, GGH potentially represents a marker for chemosensitivity to Alimta®.

UR - http://www.scopus.com/inward/record.url?scp=85002002496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002002496&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11228

DO - 10.21873/anticanres.11228

M3 - Article

VL - 36

SP - 6319

EP - 6326

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -